Pinnacle Wealth Management Advisory Group LLC Makes New $534,000 Investment in Astrazeneca Plc $AZN

Pinnacle Wealth Management Advisory Group LLC bought a new stake in Astrazeneca Plc (NYSE:AZN) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,707 shares of the company’s stock, valued at approximately $534,000.

A number of other hedge funds have also modified their holdings of AZN. IHT Wealth Management LLC increased its position in Astrazeneca by 0.3% during the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock worth $3,076,000 after buying an additional 54 shares in the last quarter. Visionary Wealth Advisors boosted its position in Astrazeneca by 1.5% during the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after acquiring an additional 60 shares during the last quarter. Vista Investment Management grew its stake in Astrazeneca by 0.3% in the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after acquiring an additional 60 shares during the period. Kestra Investment Management LLC grew its stake in Astrazeneca by 1.9% in the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares during the period. Finally, Luken Investment Analytics LLC raised its holdings in Astrazeneca by 4.3% in the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after acquiring an additional 64 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Astrazeneca Price Performance

Shares of Astrazeneca stock opened at $188.58 on Monday. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The stock has a market capitalization of $292.47 billion, a P/E ratio of 28.32, a PEG ratio of 1.64 and a beta of 0.25. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The business’s fifty day moving average price is $184.66 and its 200 day moving average price is $187.16.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, research analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Friday. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Weiss Ratings cut Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Finally, Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.